Answers are grounded in this paper and cite their sources.
Aripiprazole is the first approved atypical antipsychotic with a mechanism of action that exerts a partial agonism with high affinity at Dopamin D2- and Serotonin-5-HT1A-receptors as well as an antagonism at Serotonin-5-HT2A-receptors. Aripiprazole provides good clinical effectiveness and a favorable profile of safety and tolerability. The special pharmacodynamics of aripiprazole are described herein.
No takes yet. Share an insight, caveat, or question.
Gründer et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: